Immune thrombocytopenic purpura (ITP) is the most frequent cause of sudden onset thrombocytopenia in healthy children. In children, it usually emerges after an infection or a vaccination. It is an acquired disease, coursing with thrombocytopenia developing as an outcome of a decrease in the lifespan of platelets caused by autoantibodies formed against platelets \[[@ref1], [@ref2]\].

Celiac disease (CD) is an immunological disease induced by intolerance of the small bowel to gluten. Growth retardation and chronic diarrhea are the most frequently seen manifestations \[[@ref3]\]. In addition to the typical findings of malabsorption, many autoimmunological disorders may accompany the disease, or there may be extraintestinal findings, such as growth retardation, developmental delay, impaired hepatic function, skin manifestations, osteoporosis, or hematological disorders \[[@ref4], [@ref5]\]. As a result of having similar autoimmune mechanisms, in some publications, CD has been reported as a risk factor for ITP \[[@ref6]\]. The aim of this article was to evaluate the frequency of CD in a group of patients and compare the results with literature data.

MATERIALS AND METHODS {#sec1-2}
=====================

A total of 29 patients with a diagnosis of ITP whose follow-up and treatment were ongoing at the Department of Pediatric Hematology and Oncology of the Pamukkale University Faculty of Medicine were included in the study. CD manifestations, and anti-endomysial antibody (EMA), tissue transglutaminase antibody (tTG), and immunoglobulin A (IgA) levels were evaluated. Age, gender, platelet count at the time of admission, and duration of thrombocytopenia were recorded. Based on the duration of the disease, thrombocytopenia was classified as acute (\<3 months), persistent (3--12 months), or chronic (\>12 months) thrombocytopenia. EMA and tTG positivity was confirmed with endoscopic examination and histological analyses. The results were compared with literature data. The study was approved by the ethics committee of Pamukkale University (2017/01--10.01.17). Written, informed consent was obtained from the parents of all patients.

Statistical analyses {#sec2-1}
--------------------

All descriptive statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA). Fisher chi-square test was used for the comparison of categorical variables.

RESULTS {#sec1-3}
=======

Thirteen female (44.8%) and 16 male (55.2%) patients with a collective mean age of 7.2±4.7 years (range: 7 months-17 years) were included in the study. Mean platelet count at admission was 13,440±11,110/mm^3^ (range: 2000--41,000 mm^3^). The type of ITP was classified based on the duration of thrombocytopenia as acute (n=12; 41.4%), persistent (n=6; 20.7%), or chronic (n=11; 37.9%). Clinical and laboratory characteristics of the patients are provided in [Table 1](#T1){ref-type="table"}.

###### 

Characteristic features of the study participants

  Patient no.   Gender   Age        Platelet count(/mm^3^)   Duration of thrombocytopenia   tTG Ig A level (U/mL)   Ig A level (mg/dL)   Type
  ------------- -------- ---------- ------------------------ ------------------------------ ----------------------- -------------------- ------------
  1             Female   9 years    28,000                   5 months                       24.2                    420                  Persistent
  2             Female   15 years   11,000                   1 month                        2.94                    48                   Acute
  3             Female   8 years    31,000                   17 months                      5.2                     301                  Chronic
  4             Female   9 years    7000                     2 months                       1.19                    74                   Acute
  5             Male     4 years    1000                     1 month                        0.99                    38                   Acute
  6             Male     7 months   16,000                   6 months                       0.96                    36                   Persistent
  7             Male     2 years    24,000                   1 month                        0.45                    42                   Acute
  8             Male     4 years    25,000                   1 month                        1.66                    44                   Acute
  9             Male     10 years   20,000                   6 months                       0.74                    90                   Persistent
  10            Female   6 years    21,000                   1 month                        0.65                    106                  Acute
  11            Male     16 years   2000                     18 months                      0.89                    148                  Chronic
  12            Male     3 years    3000                     1 month                        1.13                    149                  Acute
  13            Male     4 years    9000                     8 months                       3.1                     47                   Persistent
  14            Male     10 years   15,000                   3 years                        1.69                    253                  Chronic
  15            Male     1 year     11,000                   1 year                         0.89                    86                   Chronic
  16            Female   15 years   2000                     1 month                        2.06                    71                   Acute
  17            Female   9 years    9000                     2 years                        1.04                    105                  Chronic
  18            Female   5 years    3000                     1 month                        2.1                     162                  Acute
  19            Male     3 years    4000                     4 years                        1.72                    67                   Chronic
  20            Female   8 months   41,000                   18 months                      3.2                     72                   Chronic
  21            Female   6 years    2000                     6 months                       1.39                    168                  Persistent
  22            Female   9 years    29,000                   6 months                       1.55                    80                   Persistent
  23            Female   10 years   15,000                   1 month                        4.44                    142                  Acute
  24            Male     17 years   29,000                   5 years                        3.12                    99                   Chronic
  25            Female   7 years    4000                     2 years                        4.97                    93                   Chronic
  26            Male     3 years    15,000                   1 month                        2.17                    33                   Acute
  27            Male     4 years    1000                     2 months                       3                       138                  Acute
  28            Male     8 years    2000                     4 years                        1.39                    217                  Chronic
  29            Male     12 years   10,000                   18 months                      1.2                     113                  Chronic

Ig A: Immunoglobulin A; tTG: tissue transglutaminase.

Examination for the presence of CD revealed tTG IgA: 24.1 U/mL (\<20 U/mL) and EMA positivity in 1 patient, a 9-year-old female with weight of 22 kg (3--10 percentile) and height of 118 cm (\<3 percentile). Some notable laboratory parameters were as follows: white blood cell count: 6360/mm^3^, hemoglobin: 11.4 g/dL, platelet count: 28,000/mm^3^, aspartate aminotransferase: 174 IU/L, alanine aminotransferase: 193 IU/L, lactate dehydrogenase: 914 U/L, ferritin: 42 ng/mL, iron: 38 ug/dL, total iron binding capacity: 300 ug/dL, vitamin B12: 284 pg/mL, folate: 9.9 ng/mL, prothrombin time: 12.1 seconds, partial thromboplastin time: 28 seconds, international normalized ratio: 1.08, free thyroxine: 1.39 ng/dL, and thyroid stimulating hormone: 3.21 uIU/mL. In addition to thrombocytopenia, the patient had impaired liver function and growth retardation. On peripheral smear, no atypical cells or blast cells were seen, and an average of 2 platelets were noted in every microscopic field of view. Histopathological examination of bone marrow aspiration biopsy specimen revealed an increase in the number of immature-mature megakaryocytes without any blast cells. The patient underwent endoscopic biopsy with the initial diagnosis of CD, and histopathological analysis revealed the presence of severe mucosal injury, villous atrophy, increase in the number of intraepithelial lymphocytes, and cryptic hyperplasia ([Figure 1](#F1){ref-type="fig"}). Histopathological diagnosis was reported as consistent with Stage 3c CD based on modified Marsh classification. No treatment was administered due to the lack of any finding of active bleeding and platelet count greater than 10,000/mm^3^. The patient was started on a gluten-free diet. One month later, platelet count had risen to 87,000/mm^3^. At fifth month of dietary therapy, platelet count of the patient was within normal limits.

![Histopathological examination of the biopsy material of the patients revealed villous atrophy, increase in the intraepithelial number of lymphocytes, and cryptic hyperplasia.](NCI-4-160-g001){#F1}

In our study, the frequency of CD observed in our ITP patients was not significantly different from the results of previously performed studies related to the incidence of CD ([Table 2](#T2){ref-type="table"}).

###### 

Comparison of our results with results of other studies

                      Number of patients with CD   Number of patients without CD   Total number of patients   Frequency %   p
  ------------------- ---------------------------- ------------------------------- -------------------------- ------------- ---------
  Present study       1                            28                              29                         3.4           
  Dalgıç et al.       95                           20,095                          20,190                     0.5           p=0.129
  Demirçeken et al.   10                           990                             1000                       1             p=0.271
  Ertekin et al.      11                           1252                            1263                       0.8           p=0.239
  Cilleruelo et al.   15                           1276                            1291                       1.1           p=0.301

p\<0.05 significant; CD: Celiac disease.

DISCUSSION {#sec1-4}
==========

In cases of CD, generally, the clinical findings become manifest due to intestinal mucosa injury and resultant malabsorption \[[@ref7]\]. As a result of deficient intestinal absorption, and as an autoimmune disease, various hematological symptoms can be seen in CD. Treatment-resistant iron deficiency is the most frequently seen hematological disorder seen in atypical CD \[[@ref7], [@ref8]\]. In addition to iron deficiency, folic acid, and vitamin B12 deficiencies may be also seen \[[@ref7]\]. In a study performed in our country, 21 of 22 patients diagnosed as CD, iron deficiency anemia was detected. Among them, 7 also had vitamin B12 deficiency, and folic acid deficiency was observed in 1 patient \[[@ref9]\]. In CD, apart from anemia, leukopenia and thrombocytopenia may develop due to vitamin B12 and folic acid deficiencies, and immune cytopenias, such as ITP, can develop via different autoimmune mechanisms \[[@ref8]\].

Concomitancy between CD and ITP was first described in 1988, and studies performed have demonstrated the presence of similar autoimmune mechanisms in the pathogenesis of both diseases \[[@ref10]\]. It has been determined that the native immune system is important in the pathogenesis of CD, and that toll-like receptors (TLRs) also play a key role \[[@ref11]\]. Zanoni et al. \[[@ref12]\] demonstrated that in some cases of CD, tTG antibodies induce TLR4 activation. Presumably, TLR4 expression in platelets leads to thrombocytopenia \[[@ref13]\].

CD is a frequently seen disease in the community; however, diagnosis can be overlooked due to its multivariant symptoms \[[@ref14]\]. In a study performed in our country that screened 20,190 children, CD prevalence was detected at 0.47% \[[@ref15]\]. Demirçeken et al. performed a study of tTG antibodies among healthy children aged 2 to 18 years who presented at the hospital, and found a prevalence of CD of 1% \[[@ref16]\]. In another study performed in Turkey, CD was detected in 11 of 1263 children \[[@ref17]\]. Cilleruelo et al. \[[@ref18]\] evaluated 1291 newborns, and antibody positivity was found in 19 cases; 15 were diagnosed as CD based on histopathological evaluation of biopsy specimen. Prevalence of CD was found to be 1.1%. As an outcome of our study, among 29 ITP patients, antibody positivity and histopathological diagnosis of CD was detected in 1 patient. A significant difference was not found when our results were compared with literature data.

In cases of ITP associated with CD cited in the literature, an increase in platelet count to normal limit within an average of 1 year was observed with gluten-free diet and without the need for intravenous immunoglobulin or steroid treatment \[[@ref19]\]. In our patient, platelet count 1 month after initiation of gluten-free diet was 87,000/mm^3^, and at 5 months, value was normal.

In conclusion, ITP is one of the atypical findings of CD that may accompany CD due to a similar autoimmunme mechanism. Although investigation for CD is not required in every case diagnosed as ITP, in ITP patients with developmental retardation or malabsorption, considering CD in the differential diagnosis is important so as to prevent unnecessary treatment.
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